9LPI-labile plasma iron in iron overload
Section snippets
Why another assay for assessing iron overload?
Despite the success of daily DFO treatment in maintaining thalassemia major patients in negative iron balance over more than three decades, a significant number of patients have apparently developed serious and often fatal heart conditions.25, 26 In many cases these conditions could be attributed to iron accumulation in the heart rather than the liver due to their low correlations with liver iron or circulating ferritin.9, 10, 11, 12, 13, 14, 15, 16, 27, 28, 29 The proposed view is that the
LPI Levels in thalassemia
A new high-throughput technology (FeROS, Aferrix Ltd) was recently devised for assessing LPI in the clinical setting and has already been applied to more than 5000 serum samples, including patients with thalassemia (major and intermedia)22, 23, 34, hemochromatosis22, 33, diabetes35, dysmetabolic hepatosiderosis33, and myelodysplasmic syndrome.36 The assay is based on the capacity of LPI to generate reactive oxygen radicals when prompted with ascorbate in a manner blockable by specific iron
Summary
LPI values obtained following an extended drug washout period (basal LPI levels) provide a means for evaluating the efficacy of treatment in maintaining the individual at low levels of exposure to labile plasma iron.
LPI values vary among iron-overloaded patients in relation to the regimen of chelation and time of blood withdrawal. Although the basal LPI levels decline relatively faster than other iron-related parameters, they correlate linearly with serum ferritin levels as well as with
Acknowledgements
This work was supported in part by The European Community 5th Framework QLRT-2001-00444 (nutrient iron toxicity) and by Apopharma Inc, Ont., Canada.
References (36)
Pathophysiology of thalassaemia
Baillieres Clin Haematol
(1998)- et al.
Orally active iron chelators
Blood Rev
(2002) - et al.
Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease
Semin Hematol
(2001) - et al.
Role of deferiprone in chelation therapy for transfusional iron overload
Blood
(2003) - et al.
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility
Lancet
(2003) - et al.
Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool
Blood
(2003) - et al.
Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease
Blood
(2004) - et al.
The importance of non-transferrin bound iron in disorders of iron metabolism
Transfus Sci
(2000) - et al.
Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin
Anal Biochem
(1999) - et al.
A fluorescence-based one-step assay for serum non-transferrin-bound iron
Anal Biochem
(2001)
Labile plasma iron in iron overload: redox activity and susceptibility to chelation
Blood
Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron overloaded beta-thalassaemia/HbE patients treated with an oral chelator
Blood
Chelation therapy in beta-thalassemia: an optimistic update
Semin Hematol
Survival in betathalassaemia major in the UK: data from the UK Thalassaemia Register
Lancet
Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia
Lancet
Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy
Blood
Secondary iron overload
Hematology (Am Soc Hematol Educ Program)
Design of clinically useful iron(III)-selective chelators
Med Res Rev
Cited by (259)
Prevalence and treatment of anemia and secondary iron overload in patients with a myelodysplastic syndrome: Real-world data from a multicenter cohort study
2023, Transfusion Clinique et BiologiqueOral acetylated whey peptides (AWP) as a potent antioxidant, anti-inflammatory, and chelating agent in iron-overloaded rats' spleen
2023, Journal of Functional FoodsMolecular testing in hemochromatosis
2023, Diagnostic Molecular Pathology: A Guide to Applied Molecular Testing, Second EditionHepcidin and its multiple partners: Complex regulation of iron metabolism in health and disease
2023, Vitamins and Hormones